A Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2014
At a glance
- Drugs Miravirsen (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Santaris Pharma
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
- 29 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.